Close Menu

NEW YORK (GenomeWeb News) – Biopharmaceutical firm Amgen is acquiring genomic research products firm Decode Genetics for $415 million, the companies announced today.

The all-cash deal has been approved by Amgen's board and is expected to be completed before the end of the year.

In a statement Amgen President and CEO Robert Bradway said the deal "fits perfectly" with the company's goal of pursuing the rapid development of relevant molecules for disease targets without wasting money on targets that aren't as well validated.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.